We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 03, 2021

Lenalidomide–Epoetin Alfa vs Lenalidomide Monotherapy in MDS Refractory to Recombinant Erythropoietin

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
J. Clin. Oncol 2021 Jan 13;[EPub Ahead of Print], AF List, Z Sun, A Verma, JM Bennett, RS Komrokji, K McGraw, J Maciejewski, JK Altman, PS Cheema, DF Claxton, SM Luger, RJ Mattison, TR Wassenaar, AS Artz, CA Schiffer, MR Litzow, MS Tallman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading